Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
PHASE2
This is a multicenter randomized double-blind placebo-controlled phase II c...
Status
Unknown
Location
State Institution "N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology"
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
PHASE3
The aim of study is to investigate the efficacy, safety, immunogenicity, ph...